论文部分内容阅读
目的研究恩替卡韦治疗乙型肝炎E抗原(HBeAg)阳性慢性重度乙型肝炎的临床疗效。方法 84例HBeAg阳性慢性重度乙型肝炎患者,随机分为对照组和治疗组,各42例。对照组采用阿德福韦酯治疗,治疗组采用恩替卡韦治疗。观察治疗后两组患者的丙氨酸转氨酶(ALT)复常率、HBeAg转阴情况以及不良反应情况。结果治疗组患者丙氨酸转氨酶复常率、HBeAg转阴率均高于对照组,差异有统计学意义(P<0.05),且不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论采用恩替卡韦治疗HBeAg阳性慢性重度乙型肝炎,治疗效果显著,不良反应少,值得临床推广。
Objective To study the clinical efficacy of entecavir in the treatment of hepatitis B E antigen (HBeAg) -positive chronic severe hepatitis B Methods Eighty-four patients with HBeAg-positive chronic severe hepatitis B were randomly divided into control group and treatment group, with 42 cases in each group. The control group was treated with adefovir dipivoxil, and the treatment group was treated with entecavir. After treatment, the alanine aminotransferase (ALT) recovery rate, HBeAg negative conversion and adverse reactions in both groups were observed. Results The alanine aminotransferase normalization rate and HBeAg negative rate in the treatment group were significantly higher than those in the control group (P <0.05), and the incidence of adverse reactions was lower than that in the control group (P <0.05). Conclusion Entecavir treatment of HBeAg-positive chronic severe hepatitis B, the treatment effect is significant, fewer adverse reactions, is worth clinical promotion.